Validation of an in vivo translational medicine approach for the treatment of di...
Validation of an in vivo translational medicine approach for the treatment of diabetes and diabetes complications
Validation of an in vivo translational medicine approach for the treatment of diabetes and diabetes complications
To develop new drugs for treatment of diabetes, there is an immediate need for an in vivo approach allowing the as...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
IMIDIA
Improving beta-cell function and identification of diagnosti...
27M€
Cerrado
IMIDIA
Improving beta cell function and identification of diagnosti...
27M€
Cerrado
BETATRAIN
European Training Network for Excellence in Molecular Imagin...
4M€
Cerrado
OptoBETA
Multicellular regulation of insulin secretion from pancreati...
2M€
Cerrado
T2D-EOMICS
High throughtput electrophysiological measurements coupled w...
207K€
Cerrado
HuPIPA
A Human Pancreatic Islet Perturbation Atlas (HuPIPA) to deci...
165K€
Cerrado
Información proyecto BETASCREEN
Duración del proyecto: 18 meses
Fecha Inicio: 2017-01-16
Fecha Fin: 2018-07-31
Líder del proyecto
KAROLINSKA INSTITUTET
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
149K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Validation of an in vivo translational medicine approach for the treatment of diabetes and diabetes complications
To develop new drugs for treatment of diabetes, there is an immediate need for an in vivo approach allowing the assessment of β-cell function and survival in the living organism non-invasively, longitudinally and at single-cell resolution. We therefore transplant pancreatic islets into the anterior chamber of the eye (ACE) of mice for functional microscopic imaging. In the ACE islets become vascularized and innervated, and various aspects of β-cell function and survival can be readily imaged. Functional studies demonstrate that engrafted islets in the eye serve as representative reporters of endogenous islets in the pancreas of the same animal. We have extensively in vitro tested fluorescent biosensors that reflect key-events in β-cell function and survival. Following intraocular transplantation of human islets expressing biosensors in their β-cells into healthy or diabetic mice, they will allow non-invasive, longitudinal in vivo monitoring of 1) Ca2+ handling, 2) functional β-cell mass, 3) apoptosis and 4) proliferation. Based on the in vitro tested biosensors, the major objective is to establish a robust pharma-industry in vivo platform for validating newly developed diabetes treatment lead-compounds in early drug development. This screening service shall be performed on a commercial basis. The milestone of this proposal, to be achieved within 18 months, is the validation of the in vivo platform for testing the effects of new potential diabetes medicines on human β-cell function and survival in normal and diabetic mice.